Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials
Diabetes, Obesity and Metabolism · 2024-08 · 26 (8) · 3223-3237
DOI: 10.1111/dom.15650 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.05.2024. Verfasst von Lawrence A Leiter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Obesity, Cholesterol, LDL. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG, Basel, Switzerland.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims To conduct a pooled analysis of Phase 3 trials investigating the efficacy and safety of inclisiran across glycaemic and body mass index (BMI) strata. Materials and Methods Participants were randomized 1:1 to receive 300 mg inclisiran sodium or placebo twice yearly, after initial and 3‐month doses up to 18 months, with background oral lipid‐lowering therapy. Analyses were stratified by glycaemic status (normoglycaemia, prediabetes, and diabetes) or BMI (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Canada.
- Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
- DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
- Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
ORCID-Profile: Lawrence A Leiter, Gregory G Schwartz, Kausik K Ray
Förderung
- Novartis Pharma AG, Basel, Switzerland
Zitieren
APA
Leiter, L. A., Raal, F. J., Schwartz, G. G., Koenig, W., Ray, K. K., Landmesser, U., Han, J., Conde, L. G., & Wright, R. S. (2024). Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials. Diabetes, Obesity and Metabolism, 26(8), 3223-3237. https://doi.org/10.1111/dom.15650
Vancouver
Leiter LA, Raal FJ, Schwartz GG, Koenig W, Ray KK, Landmesser U, et al. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials. Diabetes, Obesity and Metabolism. 2024;26(8):3223-3237. doi:10.1111/dom.15650
BibTeX
@article{Leiter2024,
author = {Leiter, Lawrence A and Raal, Frederick J and Schwartz, Gregory G and Koenig, Wolfgang and Ray, Kausik K and Landmesser, Ulf and Han, Jackie and Conde, Lorena Garcia and Wright, R Scott},
title = {Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION ‐9, ORION ‐10 and ORION ‐11 Phase 3 randomized trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {8},
pages = {3223--3237},
doi = {10.1111/dom.15650}
}
EUVIMED